Chimeric Antigen Receptor T Cells for Cancer Therapy
Natcher Conference Center
Building 45, Room E1/E2, National Institutes of Health
Bethesda, Maryland 20892
Thursday, March 6, 2014
The conference is jointly organized by the Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration and the Ministry of Education, Culture, Sports, Science and Technology, Japan under the US-Japan Cooperative Research Program. The goal of the conference is to exchange ideas on cutting edge areas of biomedical research and to enhance opportunities for collaborations among scientists from Japan and the US. Chimeric Antigen Receptor (CAR) T Cells for Cancer Therapy is the broad theme of this year’s meeting. Six speakers from Japan and five from the US will discuss the advances in this promising field of immnunotherapy of cancers. Treatments using CAR T cells have generated some remarkable responses in patients with advanced cancer.
Seating is limited to 150 attendees and is on a first-come-first-served basis. No prior registration is required. Attendance is free and open to the public. No videocast is arranged for the meeting. For information, please contact S. Rafat Husain by e-mailing email@example.com or phone at (301) 827-0475.